A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders

March 2, 2016

Individuals with alcohol and/or drug use disorders often fail to receive care, or evidence‐based care, yet the literature shows health economic benefits. Comparative effectiveness research is emerging that examines approved approaches in terms of real, total healthcare cost/utilization. Comprehensive retrospective insurance claims analyses are few but tend to be nationally distributed and large. The emerging […]

Read the full article →

Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: Results from a 12-month observational study.

March 2, 2016

CONCLUSION: This study is in line with some recent studies and provides further evidence that buprenorphine-naloxone is relatively safe with respect to liver injury. (Am J Addict 2013;XX:1-7). PMID: 25251050 [PubMed – as supplied by publisher] (Source: American Journal on Addictions)

Read the full article →

Buprenorphine/Naloxone Dose and Pain Intensity Among Individuals Initiating Treatment for Opioid Use Disorder

March 2, 2016

We examined dose and other factors associated with pain intensity among patients initiating BUP/NX for opioid use disorder. (Source: Journal of Substance Abuse Treatment)

Read the full article →

Table of Contents

March 2, 2016

Abstract SAMHSA Buprenorphine Meeting: Another Step Toward Lifting the Cap Fraud Probe of Sober Homes Highlights Drug‐Test Scams Bill Proposed to Provide Local Incentives to Treat Addiction N.J. Bill Would Allow Outpatient Commitment for Addiction California Certification: CAADAC + CAARR = CCAPP NASADAD Issues Public Policy Statement Endorsing Naloxone ASAM Revises Public Policy Statement on […]

Read the full article →

Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: A discrete survival and growth mixture model.

March 2, 2016

CONCLUSIONS: Generally, participants with lower baseline levels and greater decreases in craving and withdrawal during stabilization combined with slower craving and withdrawal rebound during buprenorphine taper remained opioid-free longer. This exploratory work expanded on the importance of monitoring craving and withdrawal during buprenorphine induction, stabilization, and taper. Future research may allow individually tailored and timely […]

Read the full article →

Comparative prices of diverted buprenorphine/naloxone and buprenorphine in a UK prison setting: A cross-sectional survey of drug using prisoners

March 2, 2016

A conservative estimate suggests that over 10.2 million people are held in penal institutions throughout the world, which equates to a world prison population of 144 per 100,000 (Walmsley, 2013). Internationally, drug dependence is common amongst prison populations and many are dependent upon heroin. A systematic review of international prevalence studies of prison populations for […]

Read the full article →

Buprenorphine-Naloxone Therapy in Pain Management

March 2, 2016

No abstract available (Source: Survey of Anesthesiology)

Read the full article →

Diffusion and diversion of suboxone: an exploration of illicit street opioid selling – Terry Furst R.

March 2, 2016

[Abstract unavailable] Language: en… (Source: SafetyLit: All (Unduplicated))

Read the full article →

Opioid Addicted Buprenorphine Injectors: Drug Use During And After 12-weeks of Buprenorphine-Naloxone or Methadone in the Republic of Georgia

March 2, 2016

Assess the prevalence of non-opioid drug use among opioid-addicted, buprenorphine injecting individuals in Georgia, during and after a 12-week course of buprenorphine-naloxone (Suboxone®) or methadone. (Source: Journal of Substance Abuse Treatment)

Read the full article →

Opioid Addicted Buprenorphine Injectors: Drug Use During and After 12-Weeks of Buprenorphine–Naloxone or Methadone in the Republic of Georgia

March 2, 2016

The aim of this study is to assess the prevalence of non-opioid drug use among opioid-addicted, buprenorphine injecting individuals in Georgia, during and after a 12-week course of buprenorphine–naloxone (Suboxone®) or methadone. (Source: Journal of Substance Abuse Treatment)

Read the full article →

← Previous Entries

Next Entries →